Although NSD3 is primarily dysregulated by gene amplification, it also harbors activating mutations within its catalytic SET domain reported in several solid tumors, including head and neck squamous cell carcinoma (HNSCC), lung squamous cell carcinoma (LUSC), and pancreatic cancer cells [23,57,100]. Here, NSD3 is linked to head and neck squamous cell carcinoma.